STOCK TITAN

Cybin Inc. - CYBN STOCK NEWS

Welcome to our dedicated page for Cybin news (Ticker: CYBN), a resource for investors and traders seeking the latest updates and insights on Cybin stock.

Cybin Inc. (symbol: CYBN) is a pioneering biopharmaceutical company dedicated to addressing mental health challenges through innovative therapeutics. Specializing in psychedelic-based therapies, Cybin focuses on developing novel compounds, delivery mechanisms, and protocols aimed at treating a range of psychiatric and neurological conditions.

Cybin's core business revolves around advancing clinical-stage programs designed to harness the potential of psychedelics. The company is engaged in creating safe and effective treatments for conditions such as depression, anxiety, and post-traumatic stress disorder (PTSD). Their research and development efforts highlight the transformative potential of these therapies in modern medicine.

Recently, Cybin has achieved significant milestones, including progress in their proprietary drug delivery technologies. These advancements aim to improve the administration and efficacy of psychedelic compounds, ensuring patients receive the maximum therapeutic benefit. Their innovative approach extends to developing new chemical entities (NCEs) that hold promise in the field of mental health treatment.

Financially, Cybin remains robust and committed to its growth strategy. The company has secured strategic partnerships and collaborations that bolster its research initiatives and clinical trials. These alliances are crucial in accelerating the development and commercialization of their therapeutic solutions.

Cybin's product pipeline is impressive, featuring multiple candidates in various stages of development. These include CYB001, a formulation targeting major depressive disorder, and CYB003, designed for anxiety disorders. Each product undergoes rigorous testing to ensure safety and effectiveness.

In summary, Cybin Inc. is at the forefront of revolutionizing mental health treatment through psychedelic-based therapies. Their dedication to advancing science and addressing unmet medical needs positions them as a significant player in the biopharmaceutical industry.

Rhea-AI Summary

Cybin Inc. reported its first-quarter financial results for the period ending June 30, 2022, with cash and equivalents totaling C$42.5 million. The company has made progress in its clinical development, initiating trials for its lead candidate CYB003 for major depressive disorder and CYB004 for anxiety disorders. Noteworthy highlights include the completion of over 200 preclinical studies and an expanding intellectual property portfolio with 1 patent issued and 19 pending.

Net loss for the quarter was C$13.1 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.49%
Tags
-
Rhea-AI Summary

Cybin Inc. announced that CEO Doug Drysdale will participate in a fireside chat during the Canaccord Genuity 42nd Annual Growth Conference, set for August 8-11, 2022 at the InterContinental Boston Hotel. The event will be webcast live on August 11, 2022 at 3:30 p.m. ET. Interested parties can access the live event and subsequent archived webcast on the Company's investor relations website.

Founded in 2019, Cybin is dedicated to developing safe and effective therapeutics for mental health issues, leveraging innovative technologies and partnerships.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.19%
Tags
conferences
-
Rhea-AI Summary

Cybin, a biopharmaceutical company focused on developing psychedelics into therapeutics, announced its 2022 Annual Meeting of Shareholders will be held virtually on August 15, 2022, at 10:00 a.m. ET. Shareholders of record as of July 11, 2022 will receive meeting details by around July 25, 2022. The company aims to progress its proprietary drug discovery platforms and innovative treatment regimens for mental health disorders while emphasizing the need for rigorous scientific research and clinical trials for its proposed products.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.57%
Tags
none
Rhea-AI Summary

Cybin has initiated a Phase 1/2a clinical trial for CYB003, a novel psilocybin analog aimed at treating major depressive disorder (MDD). This marks the first development of such a compound in clinical studies for MDD. The FDA granted Investigational New Drug clearance for the trial, expected to evaluate rapid antidepressant effects and safety over 12 weeks. Participants aged 21-55, currently on ineffective antidepressants, can engage in the study, which includes 11 outpatient visits and compensation up to $4,335. The trial's findings may significantly impact treatment accessibility for mental health disorders.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.04%
Tags
-
Rhea-AI Summary

Cybin has successfully acquired a Phase 1 N,N-dimethyltryptamine (DMT) study from Entheon Biomedical Corp. for CDN$1,000,000, with potential additional payments for consulting services. This acquisition is set to accelerate the clinical development timeline of CYB004, a deuterated DMT molecule aimed at treating anxiety disorders, by approximately nine months. The acquisition includes a data license agreement allowing Entheon access to crucial data. The CYB004-E study will evaluate safety and pharmacokinetics of DMT and is part of Cybin's broader commitment to advancing psychedelic therapies for mental health.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.1%
Tags
-
Rhea-AI Summary

Cybin Inc. has announced a milestone achievement involving its subsidiary, Adelia Therapeutics Inc., as per a contribution agreement dated December 4, 2020. Adelia will receive 37,366.2 Class B common shares, valued at approximately $280,247.14, in exchange for meeting project milestones. Each Class B share is priced at $7.50 and is exchangeable for Cybin shares at a ratio of 10 to 1, subject to set exchange conditions. This development aims to progress Cybin's mission of creating therapeutic solutions addressing mental health issues.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.02%
Tags
none
Rhea-AI Summary

Cybin has received FDA clearance to proceed with its Phase 1/2a clinical trial for CYB003, a novel psilocybin analog aimed at treating major depressive disorder. This milestone marks the first clinical development of a psilocybin analog. Patient recruitment will start immediately, with interim pharmacokinetic and safety data expected in Q4 2022. The trial will evaluate the impact of CYB003 on patients currently using antidepressants, assessing outcomes at two intervals post-administration. The compound demonstrated promising preclinical results indicating reduced dosing variability and improved effectiveness.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.77%
Tags
-
Rhea-AI Summary

Cybin Inc. has reported its audited financial results for the fiscal year ended March 31, 2022, along with strategic milestones for 2022. The company has received IRB approval for its Phase 1/2a trial of CYB003 in major depressive disorder, expected to start mid-2022. Cybin plans to accelerate clinical development of CYB004 for anxiety disorders and has strengthened its IP portfolio with new patents. Financially, cash and cash equivalents stand at C$53.6 million, with a net loss of C$67.6 million for the fiscal year.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.27%
Tags
-
Rhea-AI Summary

Cybin Inc. has received Institutional Review Board approval to start a first-in-human Phase 1/2a clinical trial evaluating its deuterated psilocybin analog, CYB003, for treating major depressive disorder (MDD). This milestone supports the company's goal to provide effective treatment options. The trial design includes double-blind, placebo-controlled methods, with assessments at Week 3 and Week 6 for efficacy. CYB003 aims to achieve faster onset and better tolerability compared to traditional psilocybin treatments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.18%
Tags
Rhea-AI Summary

Cybin has announced the acquisition of the largest Phase 1 DMT study in history from Entheon Biomedical Corp. This study aims to expedite the development of CYB004, Cybin's proprietary DMT molecule for anxiety treatment, by approximately nine months. Conducted in the Netherlands with 50 volunteers, this study will provide critical data on safety and dosing. The acquisition is valued at $1,000,000 CAD, with a potential additional $480,000 CAD for consulting services. The deal is expected to close within 30 days pending approval.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.4%
Tags

FAQ

What is the current stock price of Cybin (CYBN)?

The current stock price of Cybin (CYBN) is $9.61 as of December 20, 2024.

What is the market cap of Cybin (CYBN)?

The market cap of Cybin (CYBN) is approximately 185.2M.

What is Cybin Inc.?

Cybin Inc. is a biopharmaceutical company focused on developing psychedelic-based therapies for treating mental health conditions.

What does Cybin Inc. specialize in?

Cybin specializes in creating safe and effective treatments using psychedelic compounds to address psychiatric and neurological conditions.

What are the core areas of Cybin's research?

Cybin's research focuses on advancing psychedelic-based therapies, developing novel compounds, and improving drug delivery mechanisms.

What recent achievements has Cybin Inc. made?

Cybin has made significant progress in drug delivery technologies and the development of new chemical entities for mental health treatment.

Can you name some of Cybin's product candidates?

Cybin's pipeline includes CYB001 for major depressive disorder and CYB003 for anxiety disorders, among other candidates.

How does Cybin contribute to mental health treatment?

Cybin contributes by developing innovative psychedelic-based therapies aimed at providing effective treatments for various mental health conditions.

Has Cybin formed any strategic partnerships?

Yes, Cybin has established strategic partnerships and collaborations to support its research and clinical trials.

What is the significance of Cybin's drug delivery technologies?

Cybin's drug delivery technologies enhance the administration and therapeutic efficacy of psychedelic compounds.

What conditions are Cybin's therapies aimed at treating?

Cybin's therapies target psychiatric and neurological conditions such as depression, anxiety, and PTSD.

Where can I find the latest news about Cybin Inc.?

The latest news and updates about Cybin Inc. can be found on their official website and financial news platforms like StockTitan.

Cybin Inc.

NYSE:CYBN

CYBN Rankings

CYBN Stock Data

185.23M
18.64M
6.35%
36.61%
3.05%
Biotechnology
Healthcare
Link
United States of America
Toronto